WELL Health Technologies Corp. has provided a corporate update on its majority-owned subsidiary, WELLSTAR Technologies Corp., highlighting significant progress in both organic and inorganic growth. The update underscores strong momentum across key initiatives, including the expansion of OceanMD’s eReferral platform, strategic acquisitions, and a successful $62 million Series B financing round. Amir Javidan, CEO of WELLSTAR, stated that the past year has been transformative, solidifying WELLSTAR’s position as Canada’s leading digital health platform for healthcare providers. The company continues to execute on its strategy through disciplined organic growth and targeted acquisitions that enhance its technology offerings and market reach. With a clear path toward a potential public listing in 2026, WELLSTAR aims to empower clinicians with cutting-edge digital tools while delivering long-term value to shareholders. OceanMD has secured a major provincial eReferral contract as the official Referral Management System (RMS) following a competitive procurement process. The platform was selected for its seamless integration with provincial digital health systems and major electronic medical record platforms across community and hospital settings. This new contract increases WELLSTAR’s annual recurring revenue (ARR) by 16%. OceanMD now facilitates over 1.7 million eReferrals annually across Canada, serving more than 17,000 physicians and 2,500 clinics in sending roles, and over 3,300 physicians and 1,300 clinics in receiving roles—representing the largest eReferral network in the country. Clinical outcomes linked to OceanMD’s use include a 12% reduction in unnecessary MRIs, a 20% decrease in surgical wait times, and a 35-day improvement in central intake referral processing. Built-in clinical decision support tools ensure referrals are timely, appropriate, and accurate. Patient satisfaction is high, with 95% reporting improved referral experiences and 89% expressing satisfaction with wait times. Jeff Kavanagh, Co-Founder and CEO of OceanMD, emphasized the significance of winning this provincial contract, calling it a testament to the platform’s scalability, reliability, and proven impact on patient care. WELLSTAR has also advanced its acquisition strategy. Two new billing assets have been secured, including a leader in the Canadian medical billing space. The acquisitions are expected to generate approximately $4 million in annualized revenue with margins exceeding 20% and are subject to regulatory approval. Additionally, on November 1, 2025, WELLSTAR acquired Mutuo Health Solutions, the developer of AutoScribe—the core technology behind WELLSTAR’s Nexus AI Medical Scribe. The integration of Mutuo’s engineering team strengthens WELLSTAR’s ownership of critical AI IP and accelerates innovation in AI-driven clinical workflows. Financial performance for Q3 2025 reflects strong growth, with WELLSTAR reporting $18.3 million in revenue, a 67% increase year-over-year. Organic growth reached 26%, and ARR rose 63% annually, reaching $66.0 million as of September 30, 2025. The company’s recurring revenue base continues to grow steadily, underpinning long-term scalability. With the $62 million Series B financing completed, WELLSTAR is accelerating its growth strategy through strategic tuck-in acquisitions aimed at expanding its technology suite and reaching a $100 million annualized revenue run rate. The company has expanded its corporate development team and is actively pursuing a robust M&A pipeline. These efforts are expected to further solidify WELLSTAR’s leadership in AI-powered clinical and billing solutions. WELL Health Technologies remains focused on enabling healthcare providers through technology, supporting over 43,000 providers across the U.S. and Canada. WELLSTAR continues to drive innovation in the Canadian healthcare system, reducing administrative burden and improving care delivery. The company remains on track to pursue a public listing in 2026, subject to market conditions.